Despite Brexit doubts, UK life science could remain a world-beater

No need for anxiety — that’s the line at the launch of a new white paper from healthcare analytics experts IQVIA, tackling the uncertainty facing UK biopharma ahead of the country’s departure from the European Union (EU).

The paper, produced in cooperation with Public Policy Projects (PPP), makes nine key policy recommendations to the British government as it moves forward with the process of leaving the EU. At launch, however, the emphasis was on the skills and advantages Britain has, and its potential to forge a path to global life sciences leadership with or without the EU27.

Writing in the foreword, former Secretary of State for Health and current chairman of PPP and the National Health Service confederation, Sir Stephen Dorrell said: "In Tokyo, Brussels and Washington, not to mention Rio, Beijing and New Delhi, some of the brightest minds are challenging themselves to maximize their share of [the global biopharma industry],"